CA3210033A1 - Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia - Google Patents
Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia Download PDFInfo
- Publication number
- CA3210033A1 CA3210033A1 CA3210033A CA3210033A CA3210033A1 CA 3210033 A1 CA3210033 A1 CA 3210033A1 CA 3210033 A CA3210033 A CA 3210033A CA 3210033 A CA3210033 A CA 3210033A CA 3210033 A1 CA3210033 A1 CA 3210033A1
- Authority
- CA
- Canada
- Prior art keywords
- obicetrapib
- ezetimibe
- combination
- previous
- ldl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2021050109 | 2021-02-18 | ||
| NLPCT/NL2021/050109 | 2021-02-18 | ||
| PCT/NL2022/050083 WO2022177428A1 (en) | 2021-02-18 | 2022-02-18 | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3210033A1 true CA3210033A1 (en) | 2022-08-25 |
Family
ID=74844966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3210033A Pending CA3210033A1 (en) | 2021-02-18 | 2022-02-18 | Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240189311A1 (https=) |
| EP (1) | EP4294387A1 (https=) |
| JP (1) | JP2024507810A (https=) |
| KR (1) | KR20230159380A (https=) |
| CN (1) | CN117042770A (https=) |
| AU (1) | AU2022223224A1 (https=) |
| BR (1) | BR112023016682A2 (https=) |
| CA (1) | CA3210033A1 (https=) |
| IL (1) | IL304544A (https=) |
| MX (1) | MX2023009613A (https=) |
| WO (1) | WO2022177428A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12006305B2 (en) | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| WO2024165395A1 (en) * | 2023-02-07 | 2024-08-15 | Newamsterdam Pharma B.V. | Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions |
| WO2025146445A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib and ezetimibe |
| WO2025146262A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
| WO2025146446A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Pharmaceutical compositions of obicetrapib |
| WO2025147235A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Fixed dose combination composition of obicetrapib and ezetimibe |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| MX369471B (es) * | 2014-02-05 | 2019-11-08 | Dezima Pharma B V | Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares. |
| WO2017023166A1 (en) * | 2015-08-04 | 2017-02-09 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor |
| US12006305B2 (en) * | 2022-07-05 | 2024-06-11 | Newamsterdam Pharma B.V. | Salts of obicetrapib and processes for their manufacture and intermediates thereof |
| JP2025527686A (ja) * | 2022-08-22 | 2025-08-22 | ニューアムステルダム・ファルマ・ベー・フェー | オビセトラピブ及びエゼチミブ併用治療及び固定用量医薬組成物 |
-
2022
- 2022-02-18 CN CN202280015230.8A patent/CN117042770A/zh active Pending
- 2022-02-18 JP JP2023549866A patent/JP2024507810A/ja active Pending
- 2022-02-18 AU AU2022223224A patent/AU2022223224A1/en active Pending
- 2022-02-18 KR KR1020237028087A patent/KR20230159380A/ko active Pending
- 2022-02-18 CA CA3210033A patent/CA3210033A1/en active Pending
- 2022-02-18 MX MX2023009613A patent/MX2023009613A/es unknown
- 2022-02-18 BR BR112023016682A patent/BR112023016682A2/pt unknown
- 2022-02-18 EP EP22705485.5A patent/EP4294387A1/en active Pending
- 2022-02-18 US US18/277,851 patent/US20240189311A1/en active Pending
- 2022-02-18 WO PCT/NL2022/050083 patent/WO2022177428A1/en not_active Ceased
-
2023
- 2023-07-18 IL IL304544A patent/IL304544A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507810A (ja) | 2024-02-21 |
| AU2022223224A1 (en) | 2023-08-24 |
| CN117042770A (zh) | 2023-11-10 |
| IL304544A (en) | 2023-09-01 |
| MX2023009613A (es) | 2023-11-09 |
| WO2022177428A1 (en) | 2022-08-25 |
| BR112023016682A2 (pt) | 2023-11-14 |
| EP4294387A1 (en) | 2023-12-27 |
| KR20230159380A (ko) | 2023-11-21 |
| US20240189311A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240189311A1 (en) | Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia | |
| CN102526733B (zh) | 用于预防心血管事件发病的组合物 | |
| JP6196225B2 (ja) | 糖尿病新規発症低減用組成物 | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| ES2276774T3 (es) | Nueva combinacion de betabloqueante y un agente hipocolesterolemiante. | |
| JP2024527023A (ja) | Ｈｉｓ低応答者の治療 | |
| TWI741379B (zh) | 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合 | |
| KR100539066B1 (ko) | 비정상적 지질대사-유래 질환치료에 유용한 스타틴과알카노일 ｌ-카르니틴 함유 약제 조성물 | |
| US20070197602A1 (en) | Combined pharmaceutical composition | |
| CN1437484A (zh) | 含有β－受体阻滞剂和任选的降胆固醇剂的新型制剂 | |
| JPH09227371A (ja) | 粥状動脈硬化抑制剤 | |
| HK40097427A (en) | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors | |
| HUE030936T2 (en) | Use of fenofibrate or a derivative thereof for treating diabetic retinopathy | |
| MXPA01006136A (en) | Combination of cerivastatin and fibrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250129 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250129 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250129 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260303 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260313 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260313 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260413 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260414 |